RenovoRx (RNXT)
Develops targeted intra-arterial chemotherapy and commercializes the RenovoCath delivery device.
Something off on this page? Send us feedback.
Develops RenovoGem, an investigational drug-device candidate that delivers gemcitabine through RenovoCath, while commercializing RenovoCath as a stand-alone device. Its business combines clinical development with early cancer-center adoption.
Built around the trans-arterial micro-perfusion (TAMP) platform, the business has two connected tracks: RenovoGem, an investigational drug-device candidate that pairs intra-arterial gemcitabine with RenovoCath, and RenovoCath, an FDA-cleared delivery device sold on its own. RenovoCath entered its first full year of commercial activity in 2025, with expanding use at commercial cancer centers.
Execution centers on physician education, clinical direction, and cancer-center use of TAMP technology. Commercial growth depends on adoption and procedural utilization of RenovoCath, while the candidate path depends on clinical testing and regulatory milestones. The cleared device and investigational candidate remain distinct regulatory tracks.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.5M · Total debt $259.0K · Total assets $11.5M · Shareholders' equity $9.0M
- Revenue
- $909.0K
- Operating income
- −$3.2M
- Net income
- −$2.9M
No dividends on record.
| Institutions29 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 8.37% | 3.78M shares | |
| Insiders7 holders · as of Jun 24, 2026 | 13.98% | 6.31M shares | |
| Otherremainder | ≈ 77.65% | 35.05M shares |
45.13M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Orin HirschmanInsider | 9.82% | 4.43M | 13Gfiled Apr 27, 2026 ↗ |
Bleichroeder LPInstitution | 3.69% | 1.67M | 13Fas of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.20% | 1.44M | 13Fas of Jun 30, 2026 |
Ramtin AgahInsiderdirector, officer: Chief Medical Officer | 1.77% | 798,460 | Form 4filed Jan 22, 2026 ↗ |
Shaun BagaiInsiderdirector, officer: Chief Executive Officer | 1.45% | 653,397 | Form 4filed Mar 24, 2026 ↗ |
| See all 19 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 19, 2026 | Mark Voll | officer: Chief Financial Officer | +25,000 | $0.7876 |
| Mar 20, 2026 | Mark Voll | officer: Chief Financial Officer | +145,800 | $1.93 |
| Mar 20, 2026 | Shaun Bagai | director, officer: Chief Executive Officer | +36,450 | $1.93 |
| Mar 20, 2026 | Laurence Marton | director | +14,580 | $1.93 |
| Jan 21, 2026 | Ramtin Agah | director, officer: Chief Medical Officer | +10,000 | $0.9975 |
- Novocure
FDA-approved TTFields with chemotherapy for locally advanced pancreatic cancer
- Merit Medical Systems
Oncology microcatheters and embolotherapy for intra-arterial procedures
- Delcath Systems
Locoregional high-dose chemotherapy delivery for liver cancers
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| RenovoRx | $2.67 | +6.37% | $113.5M | — | — | 57.5 | +115.4% |
| Novocure | $18.30 | +2.61% | $2.08B | — | — | 3.0 | +15.6% |
| Merit Medical Systems | $91.35 | +1.33% | $5.38B | 37.2 | 20.6 | 3.4 | +9.5% |
| Delcath Systems | $15.78 | −4.77% | $572.4M | 1,275.4 | — | 6.0 | +20.6% |
| Median | 656.3 | 20.6 | 3.4 | +15.6% |